Eris Lifesciences Ltd. - Research Center
540596 ERIS Group (A) BSE data
Add to watchlist
| Results |
Half yearly
|
| Statement | |
| More |
Half yearly results in brief
(Rs crore)
| Sep ' 23 | Sep ' 22 | Mar ' 22 | Sep ' 21 | Sep ' 20 | |
|---|---|---|---|---|---|
| Sales | 821.00 | 684.13 | 586.77 | 628.96 | 564.85 |
| Operating profit | 299.99 | 267.24 | 224.41 | 259.59 | 219.95 |
| Interest | 13.39 | 14.71 | 1.74 | 1.25 | 0.41 |
| Gross profit | 297.61 | 262.05 | 237.55 | 272.44 | 223.36 |
| EPS (Rs) | 16.80 | 15.50 | 14.03 | 16.66 | 14.19 |
Half yearly
results in details
| Sep ' 23 | Sep ' 22 | Mar ' 22 | Sep ' 21 | Sep ' 20 | |
|---|---|---|---|---|---|
| Other income | 11.00 | 9.53 | 14.89 | 14.10 | 3.82 |
| Stock adjustment | -28.20 | 2.63 | -5.23 | 7.72 | -11.74 |
| Raw material | 54.81 | 63.51 | 63.22 | 54.35 | 55.19 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 171.46 | 130.14 | 107.87 | 114.31 | 106.73 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 322.94 | 220.62 | 196.51 | 192.99 | 194.72 |
| Provisions made | - | - | - | - | - |
| Depreciation | 45.16 | 30.88 | 28.61 | 22.85 | 18.27 |
| Taxation | 23.89 | 20.38 | 18.18 | 23.16 | 12.47 |
| Net profit / loss | 228.55 | 210.79 | 190.76 | 226.43 | 192.62 |
| Extra ordinary item | - | - | - | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 13.60 | 13.60 | 13.59 | 13.59 | 13.58 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 36.54 | 39.06 | 38.24 | 41.27 | 38.94 |
| GPM (%) | 35.77 | 37.78 | 39.48 | 42.37 | 39.28 |
| NPM (%) | 27.47 | 30.39 | 31.71 | 35.21 | 33.87 |
Mutual Fund Selector
Find the fund that is right for you
© 2023 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis